{
    "clinical_study": {
        "@rank": "4708", 
        "arm_group": [
            {
                "arm_group_label": "Sodium chloride pill", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test"
            }, 
            {
                "arm_group_label": "Sodium propionate pill", 
                "arm_group_type": "Experimental", 
                "description": "Study 1: pharmacokinetics Study2: Oral glucose tolerance test Study 3: intravenous glucose tolerance test"
            }
        ], 
        "brief_summary": {
            "textblock": "The aim of these studies is to firstly determine the pharmacokinetic profile of orally\n      administered enteric coated sodium propionate. Subsequently, the most efficacious dose at\n      improving glucose tolerance following an oral glucose challenge will be determined. The\n      investigators will then determine the mechanism of action of propionate, whether it acts by\n      altering beta cell function directly or by augmenting the incretin effect or both"
        }, 
        "brief_title": "Oral Propionate to Treat and Prevent Diabetes", 
        "completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetes.", 
        "condition_browse": {
            "mesh_term": "Diabetes Mellitus"
        }, 
        "detailed_description": {
            "textblock": "The NHS spends \u00a31M per hour, 10% of its yearly budget, treating diabetes. In the UK cases of\n      diabetes are expected to top 4 million by 2025. There is an urgent need for new therapies.\n      The short chain fatty acid propionate is a natural substance produced by digestion of\n      fermentable carbohydrates. Preclinical and early human data demonstrate it improves\n      pancreatic function and glucose control. The investigators aim to conduct proof of principle\n      studies to determine if oral delivery of propionate improves glucose control in patients at\n      risk of developing diabetes."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Study 1: Healthy men and women aged between 18 and 70 years with BMI between 20-25 kg/m2\n        and with normal fasting blood glucose (below5.5mmol/l and HbA1C less than 5.7% will be\n        eligible to volunteer.\n\n        Study 2: As for Study 1. Study 3: Cohort 1: Volunteers aged between 30 to 70 with a BMI\n        between 25-35 kg/m2 who do not have impaired fasting glucose and have HbA1c below 5.7%.\n\n        Cohort 2: Volunteers aged between 30 to 70 years with a BMI between 25-35 kg/m2 who have\n        impaired fasting glucose (between 5.5-7mmol/l) and HbA1C between 5.7% and 6.5%,\n\n          -  Exclusion Criteria:\u2022 Type 1 or Type 2 Diabetes\n\n               -  Gained or lost \u2265 3kg weight in the past three months\n\n               -  Taken prescription medicines having an impact on metabolism, appetite\n                  regulation, glucose homeostasis and hormonal regulation\n\n               -  Taken any dietary supplements in the last 6 months\n\n               -  Any chronic illness\n\n               -  Cardiovascular disease\n\n               -  Excess alcohol intake\n\n               -  Current smokers\n\n               -  Any gastrointestinal disorder e.g. Crohn's disease, coeliac disease or irritable\n                  bowel syndrome\n\n               -  A history of drug or alcohol abuse in the last 2 years\n\n               -  Pregnancy (all women of child bearing age will undergo a pregnancy test).\n\n               -  Pancreatitis\n\n               -  Use of medications likely to interfere with glucose metabolism, appetite\n                  regulation, hormonal balance."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "70 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "104", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 11, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01692002", 
            "org_study_id": "CRO2020 - Imperial College Lon"
        }, 
        "intervention": [
            {
                "arm_group_label": "Sodium propionate pill", 
                "description": "Sodium propionate capsule or tablet", 
                "intervention_name": "Sodium propionate", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": "Sodium chloride pill", 
                "description": "Placebo capsule or tablet", 
                "intervention_name": "Sodium Chloride", 
                "intervention_type": "Dietary Supplement"
            }, 
            {
                "arm_group_label": [
                    "Sodium chloride pill", 
                    "Sodium propionate pill"
                ], 
                "intervention_name": "Oral glucose tolerance test", 
                "intervention_type": "Procedure"
            }, 
            {
                "arm_group_label": [
                    "Sodium chloride pill", 
                    "Sodium propionate pill"
                ], 
                "intervention_name": "Intravenous glucose tolerance test.", 
                "intervention_type": "Procedure"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 20, 2012", 
        "location": {
            "facility": {
                "address": {
                    "city": "London", 
                    "country": "United Kingdom", 
                    "zip": "W12 0NN"
                }, 
                "name": "St John McMichael Centre - Imperial College London"
            }, 
            "investigator": {
                "last_name": "Gavin A Bewick, PhD", 
                "role": "Principal Investigator"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "United Kingdom"
        }, 
        "number_of_arms": "2", 
        "official_title": "Development of Orally Administered Sodium Propionate to Treat and Prevent Diabetes", 
        "overall_contact": {
            "email": "g.bewick@imperial.ac.uk", 
            "last_name": "Gavin A Bewick, PhD", 
            "phone": "02083833086"
        }, 
        "overall_contact_backup": {
            "email": "g.frost@imeprial.ac.uk", 
            "last_name": "Gary Frost, PhD"
        }, 
        "overall_official": {
            "affiliation": "Imperial College London", 
            "last_name": "Gavin A Bewick, PhD.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United Kingdom: Medicines and Healthcare Products Regulatory Agency", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "December 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Dose ranging and pharmacokinetic profile", 
                "measure": "Study 1: Peak plasma concentration of propionate", 
                "safety_issue": "No", 
                "time_frame": "at -10, 0, 15, 30, 60, 90, 120, 150, 180, 4h, 6h, 8h"
            }, 
            {
                "description": "oral glucose tolerance dose finding", 
                "measure": "Study 2: insulinogenic index", 
                "safety_issue": "No", 
                "time_frame": "0-30mins"
            }, 
            {
                "description": "Intravenous glucose tolerance test", 
                "measure": "Study 3: Incremental area under the insulin profile", 
                "safety_issue": "No", 
                "time_frame": "0-10mins"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01692002"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Plasma insulin", 
            "measure": "Insulin", 
            "safety_issue": "No", 
            "time_frame": "-10, 0, 15, 30, 60, 90, 120, 150, 180, 4h, 6h, 8h"
        }, 
        "source": "Imperial College London", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Imperial College London", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "September 2012"
    }
}